KIORA PHARMACEUTICALS Business Summary

Kiora Pharmaceuticals Inc. (KPRX) is a clinical-stage biopharmaceutical company that generates revenue primarily through strategic licensing agreements, milestone payments, and research and development (R&D) reimbursements. Its business model is centered on the development of small-molecule therapies for orphan retinal diseases, with primary segments focused on its lead asset, KIO-301—a molecular photoswitch designed to restore vision in patients with retinitis pigmentosa—and KIO-104, a next-generation DHODH inhibitor for retinal inflammation. The company leverages high-value partnerships with global players like Théa Open Innovation and Senju Pharmaceutical to fund its clinical pipeline, which also includes candidates for Stargardt disease and choroideremia. Kiora competes directly with ophthalmic-focused firms such as EyePoint Pharmaceuticals, Opus Genetics, and Exonate, positioning itself as a specialized pioneer in non-genetic, small-molecule vision restoration for late-stage retinal degeneration. Leadership is spearheaded by President and CEO Brian M. Strem, Ph.D., a seasoned executive with a pedigree in ophthalmic drug development from Allergan and Shire, and a co-founder of Okogen and Bayon Therapeutics. The executive team includes Chief Financial Officer Melissa Tosca, CPA, who brings over two decades of finance experience from Neomorph and Omniome, and Chief Development Officer Eric J. Daniels, MD, MBA, an expert in ophthalmic clinical strategy. The company is governed by a board chaired by Praveen Tyle, Ph.D., a former Novartis executive, and includes notable directors such as David Hollander, MD. Kiora is backed by prominent institutional investors, including Rosalind Advisors, AIGH Capital Management, and ADAR1 Capital Management, who collectively maintain a significant ownership stake in the company’s vision-restoration platform.